SequelSEC

Immuneering Corp IMRX

Pharmaceutical Preparations · CIK 0001790340 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$0
Fiscal year ended 2023-12-31
Operating income
-$58.41M
Fiscal year ended 2023-12-31
Free cash flow
-$49.31M
Fiscal year ended 2023-12-31

Valuation, from the filing

Public float$101.10MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today.

How this compares in its industry

Percentile among the Pharmaceutical Preparations filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Revenue YoY growth-100.0%0th
Current ratio11.35x82th

Immuneering Corp (IMRX) reported revenue of $0 and net income of -$53.47M for the fiscal year ended 2023-12-31. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from Immuneering Corp’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.

Income

Immuneering Corp income by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Revenue$0
Cost of revenue$0
Gross profit$0
Operating income-$58.41M
Net income-$53.47M
Research & development$41.62M
Weighted-average diluted sharesUnavailable
Pretax incomeUnavailable
Income tax expenseUnavailable
Diluted EPSUnavailable
Selling, general & administrativeUnavailable
General & administrative$16.76M
Selling & marketingUnavailable

Balance

Immuneering Corp balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Cash & equivalents$59.41M
Total assets$102.58M
Current assets$89.08M
Total liabilities$12.01M
Current liabilities$7.85M
Total equity incl. NCI$90.58M
Temporary (mezzanine) equityUnavailable
InventoryUnavailable
Accounts receivable$0
Goodwill$6.69M
Long-term debtUnavailable
Accounts payable$2.11M

Cash flow

Immuneering Corp cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Operating cash flow-$48.97M
Capital expenditures$342.75K
Investing cash flow$7.30M
Financing cash flow$28.44M
Net change in cash-$13.23M
Stock-based compensation$5.73M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$322.82K

Derived

Immuneering Corp derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2023-12-31
Free cash flow-$49.31M
Gross marginUnavailable
Operating marginUnavailable
FCF marginUnavailable
SBC / revenueUnavailable
Current ratio11.35x
Revenue YoY growth-100.0%
Net marginUnavailable
R&D / revenueUnavailable
CapEx / revenueUnavailable
Long-term debt / equityUnavailable
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open IMRX in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-10-29View SEC filing
10-Q · Filed 2026-08-05View SEC filing
10-Q · Filed 2026-05-15View SEC filing
10-K · Filed 2026-03-06View SEC filing
10-Q · Filed 2025-11-12View SEC filing
10-Q · Filed 2025-08-13View SEC filing

Companies in the same industry

AAGH AARD ABBV ABCL ABEO ABT ABUS ABVC ACAD ACET ACRS ACRV

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.